KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Change in Receivables (2020 - 2025)

Historic Change in Receivables for Organon (OGN) over the last 6 years, with Q3 2025 value amounting to $5.0 million.

  • Organon's Change in Receivables fell 8913.04% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$260.0 million, marking a year-over-year decrease of 163333.33%. This contributed to the annual value of -$383.0 million for FY2024, which is 28066.04% down from last year.
  • Organon's Change in Receivables amounted to $5.0 million in Q3 2025, which was down 8913.04% from -$9.0 million recorded in Q2 2025.
  • Organon's Change in Receivables' 5-year high stood at $332.0 million during Q2 2021, with a 5-year trough of -$341.0 million in Q4 2024.
  • For the 5-year period, Organon's Change in Receivables averaged around $16.3 million, with its median value being $4.0 million (2021).
  • Examining YoY changes over the last 5 years, Organon's Change in Receivables showed a top increase of 86666.67% in 2024 and a maximum decrease of 136296.3% in 2024.
  • Organon's Change in Receivables (Quarter) stood at -$99.0 million in 2021, then surged by 104.04% to $4.0 million in 2022, then skyrocketed by 575.0% to $27.0 million in 2023, then crashed by 1362.96% to -$341.0 million in 2024, then surged by 101.47% to $5.0 million in 2025.
  • Its Change in Receivables stands at $5.0 million for Q3 2025, versus -$9.0 million for Q2 2025 and $85.0 million for Q1 2025.